Mepolizumab is the first and only monthly biologic in China tested for COPD patients with blood eosinophil counts (BEC) as low as 150 cells/µL
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
The approval introduces a needle-free alternative to injectable GLP-1 therapies
India’s pharmaceutical sector stands at a pivotal inflection point
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
The approval is supported by data from three pivotal clinical trials
The study will run across 18 sites and enroll roughly 200 patients over 24 months
The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively
Applications include detailed scientific rationale and supporting clinical evidence
Subscribe To Our Newsletter & Stay Updated
